D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
CINCINNATI— Chemed Corp ’s (NYSE:CHE) President and CEO, Kevin J. McNamara, recently sold 2,000 shares of the company’s capital stock, according to a regulatory filing with the Securities and Exchange Commission. The healthcare services company, currently valued at $8.75 billion, maintains a GREAT financial health score according to InvestingPro analysis. The shares were sold on March 6 at a weighted average price of $593.67, totaling approximately $1.19 million. The transactions occurred at prices ranging between $589.18 and $600.51. Following this sale, McNamara retains ownership of 102,679 shares in the company, valued at approximately $61.4 million at current market prices. InvestingPro data shows the stock trades with notably low price volatility, with 10 additional ProTips available for subscribers analyzing this company’s comprehensive financial profile.
In other recent news, Chemed Corporation reported strong financial results for the fourth quarter of 2024. The company exceeded expectations with earnings per share (EPS) of $6.83, surpassing the forecasted $6.78. Revenue also outperformed projections, reaching $640 million against the anticipated $636.1 million. This positive performance was largely driven by the VITAS Healthcare segment, which saw a 17.4% increase in revenue year-over-year. However, the Roto Rooter segment experienced a 2.9% decline in revenue due to challenges in the residential market.
Chemed’s outlook for 2025 is optimistic, with EPS guidance set between $24.95 and $25.45, up from $23.13 in 2024. The company expects continued growth in the VITAS segment, with revenue projected to increase between 10.5% and 11.3%. Analyst firms RBC Capital Markets and Bank of America did not issue upgrades or downgrades but engaged in discussions about Chemed’s strategies and future expectations. The company’s strategic focus includes efforts to stabilize the Roto Rooter segment and capitalize on growth opportunities in the Florida hospice market. These developments reflect Chemed’s commitment to maintaining robust financial health and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.